关键词: MN-Gup glucagon-like peptide-1 probiotics short-chain fatty acids type 2 diabetes mellitus

Mesh : Animals Gastrointestinal Microbiome Diabetes Mellitus, Type 2 / metabolism microbiology Probiotics / pharmacology Bifidobacterium animalis Blood Glucose / metabolism Mice Diabetes Mellitus, Experimental Male Glucagon-Like Peptide 1 / metabolism blood Fatty Acids, Volatile / metabolism Insulin Resistance Diet, High-Fat Mice, Inbred C57BL Streptozocin Bifidobacterium

来  源:   DOI:10.3390/nu16111691   PDF(Pubmed)

Abstract:
Probiotics have garnered increasing attention as a potential therapeutic approach for type 2 diabetes mellitus (T2DM). Previous studies have confirmed that Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) could stimulate the secretion of glucagon-like peptide-1 (GLP-1) in NCI-H716 cells, but whether MN-Gup has a hypoglycemic effect on T2DM in vivo remains unclear. In this study, a T2DM mouse model was constructed, with a high-fat diet and streptozotocin in mice, to investigate the effect of MN-Gup on diabetes. Then, different doses of MN-Gup (2 × 109 CFU/kg, 1 × 1010 CFU/kg) were gavaged for 6 weeks to investigate the effect of MN-Gup on glucose metabolism and its potential mechanisms. The results showed that a high-dose of MN-Gup significantly reduced the fasting blood glucose (FBG) levels and homeostasis model assessment-insulin resistance (HOMA-IR) of T2DM mice compared to the other groups. In addition, there were significant increases in the short-chain fatty acids (SCFAs), especially acetate, and GLP-1 levels in the MN-Gup group. MN-Gup increased the relative abundance of Bifidobacterium and decreased the number of Escherichia-Shigella and Staphylococcus. Moreover, the correlation analysis revealed that Bifidobacterium demonstrated a significant positive correlation with GLP-1 and a negative correlation with the incremental AUC. In summary, this study demonstrates that Bifidobacterium animalis subsp. lactis MN-Gup has significant hypoglycemic effects in T2DM mice and can modulate the gut microbiota, promoting the secretion of SCFAs and GLP-1.
摘要:
益生菌作为2型糖尿病(T2DM)的潜在治疗方法已引起越来越多的关注。先前的研究已经证实,动物双歧杆菌亚种。乳酸MN-Gup(MN-Gup)可刺激NCI-H716细胞分泌胰高血糖素样肽-1(GLP-1),但MN-Gup是否对T2DM有体内降血糖作用尚不清楚。在这项研究中,构建了一个T2DM小鼠模型,在小鼠体内高脂肪饮食和链脲佐菌素,探讨MN-Gup对糖尿病的影响。然后,不同剂量的MN-Gup(2×109CFU/kg,1×1010CFU/kg)灌胃6周以研究MN-Gup对糖代谢的影响及其潜在机制。结果表明,与其他组相比,高剂量的MN-Gup显着降低了T2DM小鼠的空腹血糖(FBG)水平和稳态模型评估-胰岛素抵抗(HOMA-IR)。此外,短链脂肪酸(SCFA)显著增加,尤其是醋酸盐,MN-Gup组的GLP-1水平。MN-Gup增加了双歧杆菌的相对丰度,减少了大肠杆菌-志贺氏菌和葡萄球菌的数量。此外,相关分析显示,双歧杆菌与GLP-1呈显著正相关,与AUC增量呈负相关.总之,这项研究表明,动物双歧杆菌亚种。乳酸MN-Gup在T2DM小鼠中具有显著的降血糖作用,可以调节肠道菌群,促进SCFAs和GLP-1的分泌。
公众号